RankingsPricing
  1. US-listed companies
  2. Intra-Cellular Therapies, Inc.
  3. Financials
  4. Capital expenditures

Intra-Cellular Therapies, Inc.ITCI

Market cap
$13.4B
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-0+19.70%
Dec 31, 2023-0-65.42%
Dec 31, 2022-1+138.84%
Dec 31, 2021-0+22.13%
Dec 31, 2020-0-61.92%
Dec 31, 2019-1+79.01%
Dec 31, 2018-0-45.91%
Dec 31, 2017-1+1377.47%
Dec 31, 2016-0-94.31%
Dec 31, 2015-1+7216.74%
Dec 31, 2014-0-64.63%
Dec 31, 2013-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)